Study Assessing Immunogenicity and Safety of IC43 In Intensive Care Patients
NCT00876252
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
400
Enrollment
INDUSTRY
Sponsor class
Conditions
Pneumonia, Ventilator-Associated
Interventions
BIOLOGICAL:
IC43
DRUG:
Placebo
Sponsor
Valneva Austria GmbH